March 2024
-
03.22.2024 Medicines Pfizer Receives Positive CHMP Opinion for its Novel Antibiotic Combination for the Treatment of Patients with Multidrug-Resistant Infections and Limited Treatment Options
February 2024
-
02.06.2024 Medicines Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer -
02.02.2024 Medicines Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
January 2024
-
01.26.2024 Vaccines Pfizer Receives Positive CHMP Opinion for its 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) Candidate for Infants and Children
December 2023
-
12.21.2023 Medicines Hospira, Inc. Issues A Voluntary Nationwide Recall For 4.2% Sodium Bicarbonate Injection, USP ABBOJECT® Syringe; 8.4% Sodium Bicarbonate Injection, USP Lifeshield® ABBOJECT® Syringe; and Atropine Sulfate Injection, USP Lifeshield® ABBOJECT® Syringe -
12.21.2023 Medicines Hospira, Inc. Issues A Voluntary Nationwide Recall For One Lot of Bleomycin for Injection, USP 15 Units Single Dose ONCO-TAIN™ Glass Fliptop Vial Due To The Potential For Presence of Glass Particulate Matter -
12.15.2023 Medicines Pfizer Receives Positive CHMP Opinion for Ulcerative Colitis Treatment
November 2023
-
11.13.2023 Medicines Pfizer’s TALZENNA® in Combination with XTANDI® Receives CHMP Positive Opinion in the European Union for Adult Patients with Metastatic Castration-Resistant Prostate Cancer
October 2023
-
10.25.2023 Vaccines Pfizer’s PENBRAYA™ Receives Recommendation for Prevention of Meningococcal Disease in Adolescents and Young Adults from Advisory Committee on Immunization Practices -
10.13.2023 Medicines Pfizer’s ELREXFIO™ Receives Positive CHMP Opinion for Relapsed and Refractory Multiple Myeloma -
10.05.2023 Medicines FDA Grants Interchangeable Designation to Pfizer’s Biosimilar ABRILADA™ -
10.02.2023 Medicines Hospira, Inc. Issues A Voluntary Nationwide Recall For 4.2% Sodium Bicarbonate Injection, USP and 1% and 2% Lidocaine HCl Injection, USP Due To The Potential For Presence of Glass Particulate Matter